Sanofi SAN
ParisPharmaceuticalsFinancials to Sep 30, 2026 · Updated Nov 11, 2026
Moat ranks
Balance sheet
| €B | Dec '24 | Dec '25 |
|---|---|---|
| Cash | 7.6 | 7.7 |
| Securities | 0.0 | 0.0 |
| Long-term securities | 0.2 | 0.3 |
| Debt | 16.0 | 18.6 |
| Net cash | -8.1 | -10.6 |
| Equity | 77.5 | 71.4 |
- Debt / EBITDA
- 1.48×
- Debt / equity
- 0.26×
- Leases (9/30/26)
- €1.9B
- Diluted shares
- 1,197M
- Book value / share
- €59.65
- Price / book
- 1.4×
- Net cash / share
- −€8.89
- Market cap
- €103.2B
- Enterprise value
- €113.8B
Per-share record
Key indicators
| Indicator | Latest | Vs year ago | Last 8 quarters |
|---|---|---|---|
| Revenue growth | 15.7% | +14.2 pts | |
| Operating margin | 28.5% | +1.0 pts | |
| FCF margin | – | – | – |
| Capex / revenue | – | – | – |
| Dupixent sales | €5.7B | +37% | |
| Beyfortus sales | €631M | -15% | |
| Vaccines sales | €3.2B | -5% | |
| ALTUVIIIO sales | €408M | +39% | |
| Sarclisa sales | €196M | +26% |
Margins and growth from reported quarters; company KPIs as reported in results releases.
About SAN
Sanofi develops prescription medicines and vaccines. FY2025 revenue was EUR46.716bn including other revenue; the net-sales mix was 81.81% Pharma and 18.19% Vaccines.
- IP Choke Point
Patents and related IP protections are central to sustaining branded economics; when exclusivity weakens, generics and price pressure erode profitability.
- Capex Knowhow Scale
Sanofi supplies specialised vaccines through a group manufacturing network of 37 sites.
- Brand Trust
Recognized OTC brands can reduce buyer uncertainty and support repeat purchase and shelf presence.
- Oct 6, 2026
Sanofi warned that inspection-related shipment delays were expected to reduce sales of its Pompe medicines, including Nexviazyme and Myozyme. This adds a supply risk separate from the disclosed Waterford warning.
- Oct 6, 2026
Sanofi forecast a low- to mid-teens Q3 vaccine sales decline and slightly negative full-year growth. Influenza timing shifts sales to Q4, while slower RSV uptake and a new infant antibody add competitive pressure.
- Oct 6, 2026
Sanofi confirmed that Regeneron development-cost reimbursements ended in Q2 after a final EUR291m receipt. Later alliance expense rises as that benefit falls away, reducing the profit Sanofi retains from protected-product sales.
- Oct 1, 2026
Sanofi expanded its Regeneron alliance to four long-acting antibodies for USD1bn upfront and up to USD7bn in milestones. Shared future profits create a costly route to replace mature drug income.
- Oct 1, 2026
Sanofi and Regeneron settled their prior collaboration litigation, reducing uncertainty in a partnership central to Dupixent and future immunology products.
Ownership
Go deeper on SAN
- Compare stock research toolsFundamentals, valuation and screening platforms for SAN.19 tools
- See SAN's price chartNo price chart here yet. See price history and indicators.17 tools
- Read SAN's earnings callsTranscripts and audio of results calls, with management's own words.15 tools
- Investing tool dealsCurrent discounts on research, charting and tracking tools.98 deals
On this page
Financial record
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | Trend | Change 2016–25 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Per share (€) | |||||||||||||
| Revenue | 26.77 | 28.59 | 28.42 | 29.93 | 29.66 | 31.14 | 32.27 | 33.12 | 35.26 | 38.12 | 42.61 | +4.0%/yr | |
| Cash flow | 6.05 | 5.82 | 4.42 | 6.14 | 5.89 | 8.36 | 7.67 | 7.38 | 6.85 | 8.62 | – | +4.0%/yr | |
| Earnings | – | – | – | – | 9.76 | 4.95 | – | – | – | 4.04 | 3.46 | – | |
| Free cash flow | 4.44 | 4.28 | 2.84 | 4.72 | 4.23 | 6.74 | 5.99 | 5.07 | 4.31 | 5.73 | – | +2.9%/yr | |
| Capex | 1.61 | 1.54 | 1.58 | 1.42 | 1.65 | 1.62 | 1.67 | 2.31 | 2.54 | 2.89 | – | +6.7%/yr | |
| Dividends | 2.90 | 2.93 | 3.01 | 3.05 | 3.12 | 3.19 | 3.32 | 3.55 | 3.74 | 3.89 | – | +3.3%/yr | |
| Book value | 44.41 | 45.84 | 46.91 | 46.98 | 50.08 | 54.60 | 59.50 | 58.93 | 61.70 | 58.24 | 60.91 | +3.1%/yr | |
| Diluted shares (M) | 1,296 | 1,267 | 1,255 | 1,257 | 1,260 | 1,258 | 1,257 | 1,256 | 1,256 | 1,226 | 1,197 | -0.6%/yr | |
| Totals (€B) | |||||||||||||
| Revenue | 34.7 | 36.2 | 35.7 | 37.6 | 37.4 | 39.2 | 40.6 | 41.6 | 44.3 | 46.7 | 51.0 | +3.4%/yr | |
| Operating income | 6.5 | 5.8 | 4.7 | 3.1 | 14.1 | 8.1 | 10.2 | 7.0 | 7.3 | 6.3 | 6.5 | -0.3%/yr | |
| Net income | – | – | – | – | 12.3 | 6.2 | – | – | – | 4.9 | 4.1 | – | |
| Free cash flow | 5.8 | 5.4 | 3.6 | 5.9 | 5.3 | 8.5 | 7.5 | 6.4 | 5.4 | 7.0 | – | +2.2%/yr | |
| Buybacks | 2.9 | 2.2 | 1.1 | 0.0 | 0.8 | 0.4 | 0.5 | 0.6 | 0.3 | 5.0 | – | +6.3%/yr | |
| Dividends | 3.8 | 3.7 | 3.8 | 3.8 | 3.9 | 4.0 | 4.2 | 4.5 | 4.7 | 4.8 | – | +2.7%/yr | |
| Net cash | -7.9 | -5.1 | -17.5 | -15.0 | -8.3 | -9.9 | -6.1 | -7.4 | -8.1 | -10.6 | -12.0 | −€2.7B | |
| Margins & returns (%) | |||||||||||||
| Gross margin | 69.2 | 67.9 | 67.9 | 68.2 | 67.5 | 68.7 | 70.7 | 69.7 | 70.2 | 72.1 | 73.4 | +2.9 pts | |
| Operating margin | 18.8 | 16.0 | 13.1 | 8.1 | 37.8 | 20.7 | 25.1 | 16.7 | 16.4 | 13.6 | 12.7 | -5.2 pts | |
| Net margin | – | – | – | – | 32.9 | 15.9 | – | – | – | 10.6 | 8.1 | – | |
| FCF margin | 16.6 | 15.0 | 10.0 | 15.8 | 14.3 | 21.6 | 18.6 | 15.3 | 12.2 | 15.0 | – | -1.6 pts | |
| ROIC | 8.3 | 7.6 | 5.1 | 3.4 | 16.3 | 8.5 | 10.4 | 7.1 | 7.0 | 6.4 | 6.3 | -1.9 pts | |
| Return on equity | – | – | – | – | 19.5 | 9.1 | – | – | – | 6.9 | 5.7 | – | |
| R&D % of revenue | 14.9 | 15.1 | 16.5 | 16.0 | 14.8 | 14.5 | 16.0 | 15.6 | 16.7 | 16.8 | 15.9 | +1.9 pts | |
| Stock pay % of revenue | 0.7 | 0.7 | 0.8 | 0.7 | 0.7 | 0.6 | 0.6 | 0.7 | 0.7 | 0.7 | – | -0.0 pts | |
| Capex % of revenue | 6.0 | 5.4 | 5.5 | 4.7 | 5.6 | 5.2 | 5.2 | 7.0 | 7.2 | 7.6 | – | +1.6 pts | |
Change uses 2016 and 2025 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2016 base. Trend shows the fiscal years.
Moat
Moat scorecard
- Strength
- Confidence
- Structure
- Oligopoly
- Durability
- medium
- Trajectory
- widening
- Pricing power
- moderate
- Pharma (Prescription Medicines)81.8%1 claim
- Vaccines18.2%1 claim
- Opella (Consumer Healthcare - Sanofi minority stake)0.0%1 claim
Moat claims
- Applies to
- Pharma (Prescription Medicines)
- Confidence
- Durability
- medium
- Trajectory
- wideningas of Oct 8, 2026
Patents and related IP protections are central to sustaining branded economics; when exclusivity weakens, generics and price pressure erode profitability.
Dupixent Q2 2026 sales reached EUR5,154m and active patients exceeded 1.5 million by October. Protected use is expanding, but favourable US rebate adjustments boosted Q2 sales and failed programmes weaken replacement beyond the 2031 US compound-patent date.
- Dupixent sales€5.7B+37%
- ALTUVIIIO sales€408M+39%
- Sarclisa sales€196M+26%
- Ayvakit sales€203M+48%
- Dupixent active patients≥1,500,000
- Regeneron alliance expense€2.4B+75%
- Patent expiry and biosimilar entry
- Adverse IP litigation outcomes
- Compulsory licensing / government intervention
- Formulary exclusion and reference pricing
- Manufacturing quality failures can restrict supply and consume cash even while product patents remain valid
- FilingSanofi Form 20-F (FY2025) - Dupixent patent protectionFeb 17, 2026
- FilingSanofi Form 20-F (FY2025) - generic and biosimilar riskFeb 17, 2026
- SourceSanofi Q2 2026 results - Dupixent salesJul 30, 2026
- SourceSanofi and Regeneron expand the immunology AllianceOct 1, 2026
- Applies to
- Vaccines
- Confidence
- Durability
- medium
- Trajectory
- stableas of Oct 8, 2026
Sanofi supplies specialised vaccines through a group manufacturing network of 37 sites. Vaccine production requires long validation and quality testing, but the groupwide site count does not measure vaccine capacity or a cost lead over large rivals.
Q2 2026 Vaccines sales were EUR1,150m and declined 4.7% at constant exchange rates. Dynavax adds adult hepatitis B capability, but demand and comparable large rivals limit evidence of widening manufacturing returns.
- Beyfortus sales€631M-15%
- Vaccines sales€3.2B-5%
- Heplisav-B sales€113M
- Manufacturing scale-up delays or quality issues
- Platform shifts reset established process know-how
- Underutilized dedicated capacity raises unit costs
- Seasonal demand and tender timing create utilization volatility
- New infant RSV antibodies and slower vaccination uptake can reduce the demand available for existing capacity
- FilingSanofi Form 20-F (FY2025) - manufacturing complexityFeb 17, 2026
- SourceSanofi manufacturing and supply network - scaleDec 31, 2025
- SourceSanofi Q2 2026 results - Vaccines salesJul 30, 2026
- FilingSanofi October 6, 2026 aide-mémoire: Heplisav-B Q2 salesOct 6, 2026
- Applies to
- Opella (Consumer Healthcare - Sanofi minority stake)
- Confidence
- Durability
- durable
- Trajectory
- stableas of Oct 8, 2026
Recognized OTC brands can reduce buyer uncertainty and support repeat purchase and shelf presence. The evidence is company-reported and does not establish a price premium.
Opella retains established OTC brands and Sanofi retains a 48.2% equity interest, but its EUR61m H1 2026 loss does not show a stronger price premium or repeat-purchase advantage.
No reported indicator tests this claim yet.
- Private label substitution and retailer bargaining power
- Regulatory changes in OTC labeling/claims
- Brand dilution from quality/safety incidents
- SourceSanofi press release: Sanofi and CD&R close Opella transactionApr 30, 2025
- SourceSanofi press release: Sanofi and CD&R close Opella transactionApr 30, 2025
- SourceSanofi Q2 2026 results - retained Opella interestJul 30, 2026
Profile change log
- Oct 8, 2026 · business change
Opella repriced about EUR4.97bn equivalent of term loans, reducing margins by 50 basis points and expecting about EUR24m annual interest savings. Lower financing cost can help Sanofi's minority investment without proving stronger brand demand.
- Oct 8, 2026 · business change
Sanofi confirmed that Regeneron development-cost reimbursements ended in Q2 after a final EUR291m receipt. Later alliance expense rises as that benefit falls away, reducing the profit Sanofi retains from protected-product sales.
- Oct 8, 2026 · business change
Sanofi forecast a low- to mid-teens Q3 vaccine sales decline and slightly negative full-year growth. Influenza timing shifts sales to Q4, while slower RSV uptake and a new infant antibody add competitive pressure.
- Oct 8, 2026 · business change
Sanofi warned that inspection-related shipment delays were expected to reduce sales of its Pompe medicines, including Nexviazyme and Myozyme. This adds a supply risk separate from the disclosed Waterford warning.
- Oct 8, 2026 · analyst revision
Corrected Heplisav-B Q2 sales from EUR34m to the EUR113m directly reported in the October investor update. Clarified that the 37 manufacturing sites cover the group, and corrected the Efluelda June 26 event from an investigation opening to a preliminary assessment. Updated the debate for rebate adjustments, vaccine competition and ended partner reimbursements. Moat strengths, evidence status and net-sales weights are unchanged.
- Oct 8, 2026 · business change
The European Commission announced approval of EUR400m German aid for Sanofi to strengthen insulin supply resilience. The approval supports manufacturing funding but is not evidence of cash received.
- Oct 8, 2026 · business change
Sanofi signed a voluntary US agreement aligning Medicaid prices on certain medicines with prices in other high-income countries and securing a three-year tariff exemption. Price limits can change launch economics despite reduced tariff uncertainty.
- Oct 8, 2026 · business change
Sanofi raised its 2026 sales-growth guidance to around 10% at constant currencies, with business earnings per share growing slightly faster. Management expects growth to normalise in the second half.
- Oct 8, 2026 · business change
Sanofi announced the end of balinatunfib development after Crohn's disease and ulcerative-colitis trials failed internal efficacy expectations. The failure reduces the replacement pipeline.
- Oct 8, 2026 · business change
Sanofi announced that it and Regeneron stopped itepekimab development after reviewing COPD trial results and competing medicines. The decision removes a prospective respiratory growth source.
- Oct 8, 2026 · business change
FDA approved subcutaneous Sarclisa Escena with an on-body injector across existing intravenous indications. Shorter treatment and fewer infusion reactions create a convenience advantage that must convert into patient use.
- Oct 8, 2026 · business change
The European Commission adopted a preliminary assessment of possible abuse of dominance in Efluelda promotion in France and Germany. Limits on rival-product comparisons could reduce commercial freedom in enhanced influenza vaccines; no final infringement finding is established.
- Oct 8, 2026 · business change
FDA warned Sanofi's Waterford biologics plant about serious manufacturing and data-integrity failures affecting ALTUVIIIO and Thymoglobulin. Remediation costs and possible supply restrictions put launch returns at risk.
- Oct 8, 2026 · business change
The Delaware Superior Court granted summary judgment in the remaining Zantac litigation after excluding causation evidence. The ruling reduces this court's exposure; it does not settle every other jurisdiction.
- Oct 8, 2026 · business change
US tax reform triggered a EUR1,193m charge for deemed foreign-profit repatriation and deferred taxes. The charge depressed profit separately from medicine demand.
- Oct 8, 2026 · analyst revision
Verified annual and interim filings and direct regulator evidence. Corrected pre-IFRS 16 finance-lease debt and added still-consolidated Animal Health cash and borrowings in 2016. Added direct active-patient and individual launch-product histories, manufacturing risks, CSL as an enhanced-flu vaccine peer, vaccine competition and profit-quality tests. Claim strengths and revenue weights are unchanged.
- Oct 8, 2026 · business change
Sanofi and Regeneron settled their prior collaboration litigation, reducing uncertainty in a partnership central to Dupixent and future immunology products.
- Oct 8, 2026 · business change
Sanofi expanded its Regeneron alliance to four long-acting antibodies for USD1bn upfront and up to USD7bn in milestones. Shared future profits create a costly route to replace mature drug income.
- Oct 8, 2026 · business change
Sanofi proposed transferring 20 mature medicines and three sites to Cheplapharm for a 26.4% stake. The planned transfer starts in 2027 and shifts income toward an investment Sanofi would not control.
- Oct 8, 2026 · business change
The EU approved MenQuadfi for infants from six weeks, expanding the eligible population for its meningococcal vaccine.
- Oct 8, 2026 · business change
Sanofi stopped amlitelimab development in atopic dermatitis after its evidence failed to support a meaningful improvement over current care. The failure removes a prospective immunology growth source.
- Oct 8, 2026 · business change
Belén Garijo became CEO, placing pipeline execution and capital allocation under new leadership.
- Oct 8, 2026 · business change
Sanofi bought Dynavax, adding Heplisav-B and vaccine candidates to its adult immunisation portfolio.
- Oct 8, 2026 · business change
Sanofi sold control of Opella to CD&R and retained a 48.2% investment, separating OTC sales from the consolidated medicine business.
- Oct 8, 2026 · analyst revision
Full-year revenue weights replace the seasonal H1 mix; Opella now has zero consolidated revenue weight. WHO evidence adds a 13% vaccine financial-value share on a common global basis. Added sourced moat trajectories, capital-allocation debate, management and shared market links. No claim strength or evidence status changed.
- Oct 8, 2026 · business change
Sanofi sold most of its Regeneron investment, generating a EUR7,382m accounting gain. The gain increased profit without increasing recurring medicine demand.
Industry & peers
Peer map
Hover a point for its values; click a peer to compare. Dashed lines: industry medians.
Global prescription pharmaceuticals
Prescription medicines sold through retail and hospital channels at manufacturer prices worldwide, including originator brands, generics and biosimilars. Roche and CSL Vifor compete in specialty medicines, with each serving only part of this market. This broad market excludes diagnostics, medical devices and over-the-counter medicines; it is not a company-addressable revenue forecast.
- Eli Lilly
| Stocks | Moat | Gross m. | Op. m. | |
|---|---|---|---|---|
| SAN | 66 | 73.4% | 12.7% | |
| Industry median | 17 | 69 | 73.1% | 21.8% |
| Sector median | 55 | 76 | 61.5% | 17.3% |
| All stocks median | 398 | 76 | 53.1% | 20.0% |
Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.
Drivers & risks
- Aging populations and long treatment periods support demand for cancer, immune and neurological medicines. Patient need is less sensitive to the economic cycle than discretionary spending.
- New indications and better clinical outcomes expand treated populations; a successful launch can replace revenue lost when an older product loses exclusivity.
- Biologics and convenient formulations can improve care and adoption, but convenience must remain valuable against new treatments.
- Insurance coverage and healthcare access expand demand in emerging markets; reimbursement inclusion can increase volume while lowering price.
- Growing cancer treatment options and diagnostic testing can increase eligible patients; commercial value still depends on better outcomes and reimbursement.
- Patent expiry and biosimilar entry remove product protection. Clinical superiority can also take share before patents expire.
- US Medicare negotiation and international reference pricing, European reimbursement reviews and Chinese tenders constrain price. Voluntary agreements can exchange tariff relief for price concessions and change the timing of launches across countries.
- Trials, safety findings, manufacturing control failures and failed acquired drug programmes can destroy invested capital or restrict supply. Pipeline size and patents alone do not establish commercial success.
- Higher interest rates raise acquisition and financing costs. Tariffs, local production rules and biologic manufacturing requirements increase the cash needed to launch and supply products.
- Exchange-rate moves change reported sales and profit for global manufacturers. Merck reported Q2 2026 sales growth of 5% in USD and 4% excluding currency, while Roche's Swiss-franc reporting faced translation pressure.
- Vaccine eligibility, uptake and public procurement can change quickly. Pfizer’s XFG-adapted Comirnaty approval covers older people and younger people with a risk condition, constraining the eligible market.
Bulls & bears
Can Sanofi turn Dupixent cash and acquired science into durable new-product income before exclusivity and payer pressure reduce the franchise?
Arguments
What to watch
- 1Dupixent sales and active patients, net price after rebate adjustments, and Regeneron net alliance expense after reimbursements end
- 2Individual launch-product sales, FDA manufacturing remediation, trial outcomes and acquisition or license cash payments
- 3Beyfortus and Heplisav-B sales, influenza shipment timing versus vaccine uptake, Efluelda proceedings and inventory
Next check: FY2026 results: test Dupixent durability and launch productivity after Q3 Dupixent sales of EUR5,687m, against declining vaccines and higher Regeneron alliance expenses. Reconcile the upgraded business outlook with IFRS profit, tax charges, litigation and acquisition accounting.
Sources: company filings and dated sources collected for Find My Moat; market cap as of Nov 10, 2026. Not investment advice.
Free to reuse, commercially too, with a credit link. See the data license.
Moat Score 66/100 by <a href="https://www.findmymoat.com/stocks/XPAR:SAN">Find My Moat</a> (as of September 2026)Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.